Short answer
RIGEL PHARMACEUTICALS INC (RIGL) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q financials disclosed via press release exhibit: refer to Exhibit for specific revenue, earnings, and guidance figures.
RIGEL PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q financials disclosed via press release exhibit: refer to Exhibit for specific revenue, earnings, and guidance figures
- Boilerplate liability disclaimer signals routine earnings disclosure, not a restatement or material correction
- RIGL results not "filed" under Exchange Act Section 18, limiting shareholder litigation liability on these figures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RIGEL PHARMACEUTICALS INC 8-K filings
Get the next RIGL 8-K as it lands
Follow RIGL for push alerts, or ask the research agent what this filing means.